DexCom, Inc.
HealthcareNASDAQ:DXCM · NASDAQ Global Select
-$0.64 today
Vol 2.46M · Avg 5.41M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$4.8B of revenue converted into $930.4M of net income for the selected period. Gross margin is 61.8% and net margin is 19.2%, showing how much revenue survives after costs and taxes. EPS is $2.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B +15.6% | $4.0B +11.3% | $3.6B +24.5% | $2.9B +18.8% | $2.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.9B +16.9% | $1.6B +19.6% | $1.3B +29.9% | $1.0B +33.7% | $768.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.8B +14.7% | $2.4B +6.5% | $2.3B +21.5% | $1.9B +12.1% | $1.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 60.0% -0.4pp | 60.5% -2.7pp | 63.2% -1.5pp | 64.7% -3.9pp | 68.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $594.9M +7.7% | $552.4M +9.2% | $505.8M +4.5% | $484.2M -19.9% | $604.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.3B +0.4% | $1.3B +8.5% | $1.2B +17.6% | $1.0B +24.3% | $810.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.9B +2.6% | $1.8B +8.7% | $1.7B +13.4% | $1.5B +5.5% | $1.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $251.8M +15.7% | $217.7M +17.0% | $186.0M +19.3% | $155.9M +53.0% | $101.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.4B +43.7% | $945.7M +3.2% | $916.7M +62.2% | $565.3M +49.7% | $377.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 29.1% +5.7pp | 23.4% -1.9pp | 25.3% +5.9pp | 19.4% +4.0pp | 15.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $911.8M +52.0% | $600.0M +0.4% | $597.7M +52.8% | $391.2M +47.2% | $265.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 19.6% +4.7pp | 14.9% -1.6pp | 16.5% +3.1pp | 13.4% +2.6pp | 10.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $112.7M -16.0% | $134.2M -0.6% | $135.0M +467.2% | $23.8M +1300.0% | $1.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $18.3M -3.7% | $19.0M -6.4% | $20.3M +9.1% | $18.6M -1.1% | $18.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $176.6M +62.0% | $109.0M -3.3% | $112.7M +28275.0% | -$400.0K +95.6% | -$9.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.1B +53.5% | $709.0M -0.2% | $710.4M +81.8% | $390.8M +52.2% | $256.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 23.3% +5.8pp | 17.6% -2.0pp | 19.6% +6.2pp | 13.4% +2.9pp | 10.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $252.1M +89.8% | $132.8M -21.4% | $168.9M +240.5% | $49.6M +24.3% | $39.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | $836.3M +45.1% | $576.2M +6.4% | $541.5M +58.7% | $341.2M +57.3% | $216.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 17.9% +3.7pp | 14.3% -0.7pp | 14.9% +3.2pp | 11.7% +2.9pp | 8.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +46.6% | $1 +1.4% | $1 +63.6% | $1 +57.1% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +47.2% | $1 +9.2% | $1 +62.5% | $1 +56.9% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $390.2M -3.6% | $404.6M +4.8% | $386.0M -0.9% | $389.4M +0.6% | $386.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $405.5M -1.7% | $412.7M -3.0% | $425.5M -0.5% | $427.5M -0.3% | $428.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$39.80B
Biogen Inc.
NASDAQ:BIIB
$29.59B
Koninklijke Philips N.V.
NYSE:PHG
$25.66B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.31B
Waters Corporation
NYSE:WAT
$23.18B
Labcorp Holdings Inc.
NYSE:LH
$21.68B
STERIS plc
NYSE:STE
$20.30B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.15B
Smith & Nephew plc
NYSE:SNN
$12.97B
Insulet Corporation
NASDAQ:PODD
$10.37B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DXCM generate?
DexCom, Inc. (DXCM) reported $4.66B of revenue in fiscal 2025.
Is DXCM profitable?
DexCom, Inc. (DXCM) reported $836.30M of net income, with a net margin of 17.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.